SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2018 / Cilt: 33 - Sayı: 1

Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma

Senem KARABULUT
Aslı ÖRMECİ ÇİFTÇİBAŞI
Murat SERİLMEZ
Derya DURANYILDIZ
Filiz AKYÜZ
Vildan YASASEVER
Sabahattin KAYMAKOĞLU
Pages
18–27
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

They may be useful markers to help clinicians reach a diagnosis of HCC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVEThe current study was an investigation of the serum levels of vascular endothelial growth factor (VEGF),interleukin 6 (IL-6), and glypican 3 (GPC-3), as potential diagnostic and prognostic indicators in cirrhoticpatients and patients with hepatocellular carcinoma (HCC) or who are predisposed to developHCC.METHODSA total of 54 HCC patients and 30 patients with cirrhosis were enrolled in this study.
📊
Key Findings & Data:The pretreatmentserum level of GPC-3, VEGF, and IL-6 was determined using an enzyme-linked immunosorbent assay.A control group of 21 healthy age- and sex-matched individuals was also included.RESULTSThe serum VEGF level was statistically significantly higher in the HCC patients compared with the controlgroup (p=0.001).
💡
Conclusion & Impact:They may be useful markers to help clinicians reach a diagnosis of HCC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVEThe current study was an investigation of the serum levels of vascular endothelial growth factor (VEGF),interleukin 6 (IL-6), and glypican 3 (GPC-3), as potential diagnostic and prognostic indicators in cirrhoticpatients and patients with hepatocellular carcinoma (HCC) or who are predisposed to developHCC.METHODSA total of 54 HCC patients and 30 patients with cirrhosis were enrolled in this study. The pretreatmentserum level of GPC-3, VEGF, and IL-6 was determined using an enzyme-linked immunosorbent assay.A control group of 21 healthy age- and sex-matched individuals was also included.RESULTSThe serum VEGF level was statistically significantly higher in the HCC patients compared with the controlgroup (p=0.001). The serum IL-6 level was also higher in the HCC patients (p=0.002) and the cirrhoticpatients (p=0.006) compared with the control group, with a statistically significant difference. Therewas also a statistically significant difference between patients with HCC and the patients with cirrhosis(p=0.001). Furthermore, the serum GPC-3 level was significantly higher in the HCC patients (p=0.009)and the cirrhotic patients (p=0.001) compared with the healthy control group.CONCLUSIONTo our knowledge, this is the first study to determine the serum values of these parameters in patientswith HCC and cirrhosis. They may be useful markers to help clinicians reach a diagnosis of HCC.

🔖

Cite This Article

KARABULUT, S., ÇİFTÇİBAŞI, A. Ö., SERİLMEZ, M., DURANYILDIZ, D., AKYÜZ, F., YASASEVER, V., KAYMAKOĞLU, S. (2022). Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma. Türk Onkoloji Dergisi, Cilt: 33 - Sayı: 1, 18–27. https://ajindex.com/articles/639260

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol 2013;5(6):311–22.
  2. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009;15(11):1301–14.
  3. Song HH, Shi W, Xiang YY, Filmus J. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 2005;280(3):2116–25.
  4. Stigliano I, Puricelli L, Filmus J, Sogayar MC, Bal de Kier Joffé E, Peters MG. Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat 2009;114(2):251–62.
  5. Torisu Y, Watanabe A, Nonaka A, Midorikawa Y, Makuuchi M, Shimamura T, et al. Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci 2008;99(6):1139–46. Filmus J. The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans. Glycoconj J 2002;19(4-5):319–23.
  6. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009;100(8):1403–7.
  7. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125(1):89–97.
  8. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306(1):16–25.
  9. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006;12(8):1175–81.
  10. Kanda M, Nomoto S, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, et al. Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol 2008;98(3):190–6.
  11. Li XM, Tang ZY, Qin LX, Zhou J, Sun HC. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 1999;18(4):511–7.
  12. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006;63(5):321–9.
  13. Cheng KS, Tang HL, Chou FT, Chou JW, Hsu CH, Yu CJ, et al. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. Hepatogastroenterology 2009;56(93):110